Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegaptanib dose-ranging trial in neovascular age-related macular degeneration
2006-000722-31Phase 3Terminated
- Sponsor
- (OSI) Eyetech, Inc
- Start
- May 2006
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pegaptanib sodium in age-related macular degeneration (AMD) (3 arms), sponsored by (OSI) Eyetech, Inc. Primary endpoints: Primary efficacy endpoint and Visual acuity assessment. Started May 2006; status: terminated.
02
Drugs
pegaptanib sodium
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2006-000722-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000722-31.